Ligand Pharma Files 2024 Executive Compensation Details
Ticker: LGNZZ · Form: DEF 14A · Filed: Apr 22, 2025 · CIK: 886163
| Field | Detail |
|---|---|
| Company | Ligand Pharmaceuticals Inc (LGNZZ) |
| Form Type | DEF 14A |
| Filed Date | Apr 22, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, annual-meeting, proxy-statement
TL;DR
Ligand Pharma dropped its 2024 exec pay report. Check out who got what.
AI Summary
Ligand Pharmaceuticals Inc. filed its DEF 14A on April 22, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes compensation details for board members such as Todd C. Davis, Tavo Espinoza, Andrew Reardon, Matthew Korenberg, and John L. Higgins, covering the years 2020 through 2024.
Why It Matters
This filing provides transparency into how Ligand Pharmaceuticals compensates its top executives and board members, which can influence investor decisions and corporate governance.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of executive compensation and does not present new financial risks.
Key Players & Entities
- LIGAND PHARMACEUTICALS INC (company) — Filer
- Todd C. Davis (person) — Board Member
- Tavo Espinoza (person) — Board Member
- Andrew Reardon (person) — Board Member
- Matthew Korenberg (person) — Board Member
- John L. Higgins (person) — Board Member
FAQ
What is the primary purpose of this DEF 14A filing?
The primary purpose of this DEF 14A filing is to provide information regarding the solicitation of proxies for the company's annual meeting of stockholders, including details on executive compensation and board member information.
For which fiscal year does this filing primarily report compensation data?
This filing primarily reports compensation data for the fiscal year ending December 31, 2024.
Who are some of the individuals listed as members in the compensation data?
Individuals listed as members include Todd C. Davis, Tavo Espinoza, Andrew Reardon, Matthew Korenberg, and John L. Higgins.
What is the company's Standard Industrial Classification (SIC) code?
The company's SIC code is 2834, which corresponds to Pharmaceutical Preparations.
When was this DEF 14A filing submitted to the SEC?
This DEF 14A filing was submitted to the SEC on April 22, 2025.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 22, 2025 by Todd C. Davis regarding LIGAND PHARMACEUTICALS INC (LGNZZ).